Alex Yu

Husband, father, son. Rooting in science for business. It begins with passion, followed by vision and execution. My opinions are my own.

[Alex Yu @JAlexYu]

@andrewpannu Thanks Andrew. Full report please.

[Alex Yu @JAlexYu]

Thanks Canada! A smoke choked, martial sky from fires thousands of miles away.

[Alex Yu @JAlexYu]

Moonrise at sunset

[Alex Yu @JAlexYu]

@DavidHongMD Science is the common language

[Friends of Cancer Research @CancerResrch]

Last chance to register! Join us Wednesday in DC or virtually for our "Unlocking Next-Generation Therapies" meeting: https://t.co/TJJgGfkPqy. This free event will bring together experts across industries to explore innovative approaches in cell therapy development.

[Alex Yu @JAlexYu]

The recent AMT-130 topline results and the ensuing regulatory debate around a potential marketing application have quickly become one of the most closely watched developments. Here are some of my thoughts on the current data…
https://t.co/K5wki4cQB2

[Alex Yu @JAlexYu]

Davis Webb is the one. Bring him home @Giants

[Alex Yu @JAlexYu]

@adamfeuerstein BBWs are typically issued when risk is clear, repeatable, and not meaningfully mitigable. Although the case is mechanistically reasonable, this single reversible case (per PRnews) is likely insufficient to trigger BBW. Likely requests long-term malignancy surveillance commitment.

[Alex Yu @JAlexYu]

Recent discoveries on the acquisition of the highest levels of human performance | Science https://t.co/0mjUk1irKA

[Alex Yu @JAlexYu]

So, $JNJ literally makes a case to compete with itself! Nothing says “flattening survive curve” quite like that. Innovation saves lives[ThumbsUp]

[Alex Yu @JAlexYu]

From Speed to Substance https://t.co/VKtO9IZNqx

[Alex Yu @JAlexYu]

Mechanism as the New Metric of Proof https://t.co/nKvNTuWVAf

[Alex Yu @JAlexYu]

this immune-related DILI in CRISPR trials could become a controllable variable rather than a showstopper, as we saw in AAV trials. The liver remains biology’s most honest reviewer — and CRISPR is learning its hard lesson in humility and translation.

[Alex Yu @JAlexYu]

CRISPR’s Hepatic Stress Test https://t.co/rro18RM9LF

[Alex Yu @JAlexYu]

and together they could trigger immune-mediated hepatocellular injury. It’s still early to conclude this is a platform failure or a calibration moment. With early risk screening, short steroid bridges, and dense liver monitoring,

[Alex Yu @JAlexYu]

There’s something profoundly satisfying about a Kaplan–Meier curve that’s completely flat—it’s the quiet signature of rigorous science and relentless work.

[Alex Yu @JAlexYu]

Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency | New England Journal of Medicine https://t.co/pENYG3px76

[Alex Yu @JAlexYu]

FDA’s CNPV pilot program redefines what priority means. The first 9 recipients reflect a shift from purely clinical innovation to national impact, manufacturing resilience, and affordability. https://t.co/9FlKUJYpKa

[Alex Yu @JAlexYu]

@Nicole_Paulk @SirenBio Cancer sucks! Wishing you a speedy recovery...